SEHK:3320Pharmaceuticals
What China Resources Pharmaceutical Group (SEHK:3320)'s Onshore Debt Refinancing Plan Means For Shareholders
China Resources Pharmaceutical Group Limited recently proposed amending its articles of association to reflect updated Hong Kong rules on treasury shares and website-based shareholder communication, while its subsidiary CR Pharmaceutical Commercial received approval in China to register up to RMB3 billion in medium term notes for refinancing interest-bearing debt.
Together, these changes highlight the group’s efforts to modernise its corporate framework and improve balance sheet flexibility...